3. (Amended) A method of Claim 1 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.

5. (Amended) A method of Claim 1 [4] wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.

6. (Amended) A method of Claim 5 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

~~7.~~ 4 (Amended) A method of Claim ~~6~~ 3 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNFα selected from the group consisting of] residues ~~of about 87-108 (SEQ ID NO:1) or~~ [and] ~~about 59-80 (SEQ ID NO:2) of hTNFα.~~ set forth in SEQ ID NO:1 or SEQ ID NO:2.

~~8.~~ 5 (Amended) A method of Claim ~~6~~ 3 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNFα to monoclonal antibody cA2.

~~9.~~ 6 (Amended) A method of Claim ~~8~~ 5 wherein the chimeric antibody is monoclonal antibody cA2.

10. (Amended) A method [for] of treating [or preventing] rheumatoid arthritis in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor alpha antibody to the individual, in therapeutically effective amounts.

11. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered simultaneously.

12. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.

13. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.

14. (Amended) A method of Claim 13 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

~~15~~ 11. (Amended) A method of Claim ~~14~~ 10 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNFα selected from the group consisting of] residues ~~of about 87-108 (SEQ ID NO:1) or~~ [and] ~~about 59-80 (SEQ ID NO:2) of hTNFα.~~ set forth in SEQ ID NO:1 or SEQ ID NO:2.

~~16~~ 12. (Amended) A method of Claim ~~14~~ 10 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNFα to monoclonal antibody cA2.

~~17~~ 13. (Amended) A method of Claim ~~16~~ 12 wherein the chimeric antibody is monoclonal antibody cA2.

18. (Amended) A method [for] of treating [or preventing] Crohn's disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor alpha antibody to the individual, in therapeutically effective amounts.

19. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered simultaneously.

20. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.

21. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.

22. (Amended) A method of Claim 21 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

~~23~~ 18. (Amended) A method of Claim ~~22~~ 17 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNFα selected from the group consisting of] residues ~~of about 87-108 (SEQ ID N:1) or~~ [and] ~~about 59-80 (SEQ ID NO:2) of hTNFα.~~ set forth in SEQ ID NO:1 or SEQ ID NO:2.

~~24~~ 19. (Amended) A method of Claim ~~22~~ 17 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNFα to monoclonal antibody cA2.

~~25~~ 20. (Amended) A method of Claim ~~22~~ 17 wherein the chimeric antibody is monoclonal antibody cA2.

26. (Amended) A composition comprising methotrexate and an anti-tumor necrosis factor alpha antibody or antigen-binding fragment thereof.

27. (Amended) A composition of Claim 26 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

~~28~~ 24. A composition of Claim ~~27~~ 23 wherein the chimeric antibody binds to one or more epitopes included in amino acids [of hTNFA selected from the group consisting] ~~of about 87-108 and about 59-80 of hTNFα.~~ residues set forth in SEQ ID NO:1 or SEQ ID NO: 2.